Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigenic peptide chain group for treating tumor and application thereof to medicine

A technology of antigenic peptides and drugs, applied in the field of malignant tumor bioimmune drugs, can solve problems such as difficult side effects and non-specificity

Inactive Publication Date: 2018-06-29
天津亨佳生物科技发展有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DCs induced by tumor-associated high-expression proteins are not strictly specific, and tissue cells other than tumors also express the same protein, so its side effects are a problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigenic peptide chain group for treating tumor and application thereof to medicine
  • Antigenic peptide chain group for treating tumor and application thereof to medicine
  • Antigenic peptide chain group for treating tumor and application thereof to medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Patient A, male, 63 years old. Lung adenocarcinoma, clinical stage IV, progressed after 5 cycles of vinorelbine combined with cisplatin chemotherapy, with multiple lung metastases. A lung lesion biopsy was taken, and 488 tumor occurrence and development-related gene panels and HLA typing chips were tested. The patient carried the EGFR C797S mutation, and the HLA typing was HLA-A: A*1002A*3102; HLA-B: B* 3101B*4013; HLA-C: C*0303C*0801; HLA-DQB1: DQB1*0402DQB1*0101; HLA-DRB1: DRB1*0405DRB1*1301.

[0065] Combination therapy (hereinafter referred to as "administration") was performed using the antigen peptide chain group for treating tumors of the present invention, once a week for a total of 10 weeks. Flow detected the specific IFN-γ secretion before, after 3 weeks, and after 10 weeks of medication, and observed the changes in tumor size with imaging at the same time points (see Figure 1 and Figure II ). The specific selected peptide chains are as follows:

[0066...

Embodiment 2

[0070] Patient B, female, 51 years old, with adenocarcinoma of the left lung, progressed after 5 cycles of chemotherapy and oral molecular targeted drug gefitinib. A lung tumor biopsy was performed, and 488 tumor occurrence and development-related gene panels and HLA typing chip tests were performed. The results showed that the patient carried the EGFR C797S mutation. HLA typing is HLA-A: A*0302A*3305; HLA-B: B*1801B*4002; HLA-C: C*0301C*0401:; HLA-DQB1: DQB1*0102DQB1*0203; HLA-DRB1: DRB1 *0301DRB1*1004.

[0071] Combination therapy was performed with the antigen peptide chain group for treating tumors of the present invention once a week for a total of 12 weeks. The specific selected peptide chains are as follows:

[0072] a) PFGSLLD, b) LMPFGSLL, c) GSLLDYVR, d) QLMPFGSLL, e) GSLLDYVRE, f) TVQLMPFGSL, g) FGSLLDYVRE, h) VQLMPFGSLLD, i) LTSTVQLMPFGS, j) GSLLDYVREHKD.

[0073] The changes in the size of lung tumors before and after treatment are as follows: image 3 shown b...

Embodiment 3-60

[0075] Example 3-60 Cancer patients of different types and degrees were taken, and 488 tumor occurrence and development-related gene panels and HLA typing chip tests were performed. All patients carried the EGFR p.C797S mutation, and different antigen peptide chain groups were used The combined form of treatment was given once a week for 12 weeks. The results of HLA*A3101-HVKITDFGR Tetramer staining and the change of lung tumor size before and after treatment in Example 3-60 are similar to those in Example 1-2, and will not be repeated here due to space limitations. The above results can all show that the antigen peptide chain group of the present invention can induce dendritic cells that produce tumors, and dendritic cells as antigen-presenting cells can present antigen information to T cells, interact with T cells, and cause T cells to produce tumors. It specifically kills tumor cells, plays a role in killing tumor cells, and the effect is obvious.

[0076] During the treat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antigenic peptide chain group for performing an individual biological immune therapy of tumors and application thereof to a medicine. The antigenic peptide chain group for treating the tumor comprises any one of SEQ ID No:1-57 or combination of at least two amino acid sequences. The antigenic peptide chain group disclosed by the invention can induce dendritic cells producing the tumor, and therefore, the dendritic cells as antigen presenting cells can present antigen information to T cells, so that a mutual interaction effect between the dendritic cells and the T cells is achieved, and the T cells produce specific killing tumor cells, so that an effect of killing tumor cells is achieved.

Description

technical field [0001] The invention belongs to the technical field of malignant tumor bioimmune drugs, and in particular relates to an antigen peptide chain group for individualized biological immunotherapy of tumors and its application in medicine. Background technique [0002] At present, the global incidence of malignant tumors is increasing, the mortality rate is high, and the prognosis is poor. The National Cancer Prevention and Research Office of the National Cancer Center released the largest comprehensive analysis of cancer survival data in China in the International Journal of Cancer. The data shows that the 5-year survival rate of cancer in China is 30.9%, which is far lower than that of developed countries; at the same time, the survival rate of rural patients is only half of urban patients. In developed countries, prostate cancer and breast cancer account for the majority. In China, cancers such as lung cancer, gastric cancer, and liver cancer are more common, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08C07K19/00A61K38/08A61K38/10A61P35/00
CPCC07K7/06A61K38/00C07K7/08C07K2319/00
Inventor 刘玉强霍冲
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com